Date: 2016-07-12
Type of information: Opening of new premises
Compound:
Company: Cambrex (USA - NJ)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On July 12, 2016, Cambrex, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), announced the completion and validation of a $50 million state-of-the-art production and warehousing expansion at its cGMP Charles City, Iowa site.
- The new 7,500 sq. ft. multi-purpose manufacturing facility will initially add a total of 70m3 of glass lined and Hastelloy reactors ranging in size from 7 to 16m3, along with 6mm2 Hastelloy agitated filter dryers to provide a flexible, multi-purpose configuration, and will be capable of handling potent APIs at an Occupational Exposure Limit (OEL) of down to 1?g/mm3. The facility complements the three existing large scale manufacturing facilities at the Charles City site.
- The 36,000 sq. ft. cGMP warehouse provides general cGMP storage for 2,720 pallets and segregated 2-8°C refrigerated storage for 360 pallet spaces and features Distributed Control System monitoring and control for temperature and humidity. The facility employs a barcode system for automated bin location and has a dedicated sampling room with appropriate extraction and handling for flammable materials.
- Additionally, a further 7,500 sq. ft. manufacturing shell has been constructed which will be fitted out to customer specification.
- Cambrex has invested over $125 million at the Charles City site since the company acquired it in 1991.
Financial terms:
Latest news:
Is general: Yes
